The short answer: the warning is specific, not a verdict on every thyroid condition
If you have hypothyroidism or take levothyroxine, seeing “thyroid” in a warning can be alarming. The US boxed warnings for Mounjaro and Zepbound, which contain tirzepatide, and Wegovy, which contains semaglutide, are specifically about thyroid C-cell tumours and medullary thyroid carcinoma (MTC). The labels say these tumours occurred in rodents and that the relevance of those findings to humans remains unknown [1, 2, 3].
The stated contraindication is a personal or family history of MTC, or multiple endocrine neoplasia syndrome type 2 (MEN2). Ordinary hypothyroidism and Hashimoto's disease are not listed as separate contraindications. That is not automatic permission to start treatment; it means these diagnoses are not interchangeable. The clinician needs the exact thyroid diagnosis, treatment, results and any family tumour history before deciding whether the medicine is appropriate [1, 2, 3, 4].
This article does not claim that human risk is zero, and it does not treat every thyroid condition as an exclusion. It separates a specific warning from still-uncertain human evidence and from a common condition such as hypothyroidism. Medicine selection, dosing and other adverse effects are covered in a separate guide so that the decision is not reduced to this warning alone [1, 2, 3].
MTC and MEN2 are different from hypothyroidism and Hashimoto's disease
The thyroid contains different cell types. C cells produce calcitonin, and MTC begins in those cells. The hormones involved in energy regulation and metabolism, including T4, come from different follicular cells. MTC is therefore not another name for an underactive thyroid, and a TSH result is not a test that excludes MTC [4, 5].
MEN2 is an inherited syndrome associated with a pathogenic change in the RET gene and a higher likelihood of MTC and other endocrine tumours. The useful family history is more precise than “someone in the family had a thyroid problem.” It asks whether the diagnosis was medullary thyroid cancer, MEN2, or a documented RET variant. If old information is incomplete, the clinician may request the pathology report or arrange endocrine or genetic assessment rather than guess [4].
Hypothyroidism means the body does not produce enough thyroid hormone, and Hashimoto's disease is a common autoimmune cause. Usual treatment replaces the missing hormone with levothyroxine and follows thyroid tests. Hypothyroidism or Hashimoto's disease does not erase a separate MTC or MEN2 history, but neither condition becomes the C-cell tumour named in the warning merely because it involves the thyroid. Keeping those issues separate prevents stopping essential treatment or excluding a medicine based only on the word “thyroid” [5, 6].
Where did the warning come from? Rodent findings do not settle human risk
In carcinogenicity studies used during medicine development, semaglutide caused thyroid C-cell tumours in rodents, while tirzepatide produced an exposure- and duration-related increase in C-cell tumours in rats. Those findings are the origin of the boxed warning. The labels do not say that human MTC has been established as a causal effect; they explicitly state that the human relevance of the animal findings is undetermined [1, 2, 3].
At the same time, “undetermined” does not mean “impossible.” MTC is rare, and trials designed primarily for diabetes or weight outcomes may not be large or long enough to settle a rare harm that could develop over years. Regulators therefore retain the warning and its specific contraindication even while some human data are relatively reassuring over shorter periods [1, 2, 3].
The practical conclusion is restrained. A rodent experiment should not be turned into a claim that the medicine causes cancer in every user, while a human study without a clear increase should not erase the warning. Safer decisions follow the label: exclude personal or family MTC and MEN2, discuss any thyroid nodule or neck symptoms, and interpret evolving human research within its limits [1, 2, 3, 9, 10].
What do human studies show? Important uncertainty remains
Human studies have not all produced the same signal. A 2024 analysis of randomised trials found a relative increase in thyroid cancer overall, but the absolute increase was small and the statistical result was fragile; there was no separately significant increase in MTC. An earlier French healthcare-data study found an association, but an observational association cannot by itself establish that the medicine caused the outcome [9, 13].
On the other side, a large Scandinavian study found no substantial increase over an average follow-up of about four years, and an international study using six databases found no evidence of an increase during a shorter follow-up period. These analyses are informative, but they cannot close the question after longer exposure or precisely exclude a very rare increase [10, 11].
A newer analysis of randomised trials covering incretin therapies, including GLP-1 receptor agonists and dual therapy, found no statistically significant increase, yet rated the certainty of evidence very low because events were rare and estimates imprecise [12]. The honest answer is therefore neither “completely safe” nor “causes cancer.” Current human evidence has not settled long-term risk, and the label contraindications remain the practical rule [1, 2, 3, 9, 10, 11, 12, 13].
Before a decision: the exact diagnosis matters more than “I have a thyroid problem”
Prepare a specific history. Do you have hypothyroidism, Hashimoto's disease, a nodule, a goitre, previous surgery, or cancer? If cancer was diagnosed, was it medullary, papillary, follicular, or is the type unknown? Which relative was affected, and is a pathology report or genetic result available? Those details change the meaning of the warning far more than a single TSH value [1, 2, 3, 4].
A personal or family history of MTC and the presence of MEN2 are contraindications in the labels, even if the person feels well and thyroid-function tests are normal. Previous papillary cancer or a benign nodule is not the same stated contraindication, but that does not provide self-clearance. A clinician still needs to review the type, previous treatment, surveillance and any unresolved symptoms or investigations before deciding about treatment [1, 2, 3, 4].
If all you know is that a relative had thyroid surgery, do not assume it was MTC and do not assume it was harmless. Try to obtain the diagnosis or report. If you have an unevaluated lump or persistent hoarseness, a weight-management injection is not a substitute for neck assessment. The aim is a decision based on verifiable information rather than general fear or general reassurance [1, 2, 3, 4].
If you have hypothyroidism and take levothyroxine, do not alter treatment yourself
Levothyroxine replaces missing hormone, with the aim of keeping thyroid function in the range set by the clinician. Do not stop it on injection day or raise or lower it because appetite or weight has changed. The official levothyroxine label warns against using excess thyroid hormone for weight loss because excessive doses can cause serious toxicity. Keep the way you take it consistent and review any change in timing, supplements or other medicines with the clinician [5, 6, 7, 8].
The tirzepatide and semaglutide labels state that these medicines delay gastric emptying and may affect absorption of oral medicines, with caution advised for medicines that require close monitoring. That is a reason for review, not evidence that every user needs a levothyroxine dose change, and it does not prove that an injection has made levothyroxine ineffective [1, 2, 3].
After substantial weight loss, or if new symptoms appear such as palpitations, tremor, heat intolerance, unusual fatigue, constipation or feeling cold, discuss the timing of TSH and free T4 with the clinician. Results are interpreted alongside the dose, how it is taken and the timing of the last adjustment. If the levothyroxine dose itself changes, usual follow-up allows enough time for hormone levels to stabilise, often about six to eight weeks, rather than testing two days after a weight change [5, 6]. If the scale is stalled and you wonder about medications, read about thyroid dose and weight plateaus.
Are calcitonin tests or ultrasound required, and what are the red flags?
The labels state that the value of routine calcitonin testing or thyroid ultrasound for early MTC detection in every user is uncertain. Calcitonin can rise for other reasons, while thyroid disease and nodules are common, so indiscriminate screening may lead to unnecessary procedures. Do not order a routine “thyroid package” solely because you are discussing Mounjaro or Wegovy [1, 2, 3].
That differs from a nodule found on examination or imaging, or an elevated calcitonin result obtained for a clinical reason. Those findings need directed evaluation, and the clinician may choose repeat testing, ultrasound or endocrine referral according to the context. TSH assesses regulation of thyroid function; it is not a substitute for evaluating a neck mass and is not an MTC screening test [1, 2, 3, 4, 5].
Seek prompt assessment for a new neck swelling or lump, difficulty swallowing, difficulty breathing, or persistent hoarseness. Severe or rapidly worsening breathing difficulty needs urgent care. These symptoms do not automatically mean cancer and have many possible causes, but they should not be ignored or diagnosed online. Do not wait for symptoms if you already know about MTC or MEN2; the history itself is enough to apply the stated contraindication [1, 2, 3, 4].
The next step: a structured review before any decision
Before the appointment, record the name and dose of your thyroid medicine, how you take it, recent TSH and free T4 results if available, and any recent change in weight or symptoms. Also record the exact name of any personal or family thyroid cancer, the relationship, and whether MEN2, RET testing or a pathology report is involved. That list supports a more accurate review than simply saying “I have a thyroid problem” [1, 2, 3, 4, 5, 6].
The medical team at La Rose can review the individual picture at the Maadi and Fifth Settlement, New Cairo branches: whether a label contraindication is present, whether hypothyroidism is monitored and stable, and whether a symptom or nodule needs a separate assessment pathway. Decisions about tirzepatide or semaglutide, thyroid-test timing and levothyroxine dose remain individual clinical decisions; do not start, stop or change any dose yourself [1, 2, 3, 5, 6, 8].
If the history includes MTC or MEN2, disclose it before discussing a prescription because the contraindication is explicit. If the issue is hypothyroidism alone, do not hide it and do not treat it as automatic refusal; bring the information and let the assessment distinguish thyroid function, tumour history and the weight-treatment goal. A neck or breathing red flag takes priority over a routine weight-management appointment [1, 2, 3, 4]. For non-urgent concerns, you can book a consultation with the medical team. For the wider picture, read what the WHO GLP-1 obesity guideline recommends.
